Harrow to present Phase 3 BYQLOVI post-cataract inflammation trial data at AAO 2026

• Harrow flagged 15 clinical research presentations across AAOpt 2026 and AAO 2026, spanning dry eye, VKC, ocular inflammation, blepharitis.
• Most results have not yet been presented; AAOpt runs Sept. 30–Oct. 3, 2026, AAO runs Oct. 9–12, 2026.
• Dry-eye studies on VEVYE focus on sustained safety signals, faster symptom relief, improved patient-reported vision, supported by real-world evidence.
• Verkazia presentations in pediatric VKC center on symptom relief trajectory, reduced reliance on steroid rescue, tolerability, backed by pooled analyses.
• AAO posters on BYQLOVI highlight Phase 3 cataract-surgery data supporting post-operative inflammation and pain control with an emphasis on safety.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harrow Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609300700PRIMZONEFULLFEED9836628) on September 30, 2026, and is solely responsible for the information contained therein.